Epivir Articles
EU Approval Of GWs AIDS Treatment Epivir
12 August 1996
Profitability Continues For BioChem Pharma
12 August 1996
Europe Stock Comment
5 August 1996
Lamivudine Study Halted Early On Ethical Grounds
29 July 1996
Basis For Lamivudine Efficacy
29 July 1996
How Feasible Is HIV Eradication?
22 July 1996
GW's Nucleoside 1592U89 Shows Early Promise
22 July 1996
No Euphoria Over AIDS Drugs Among Investors
22 July 1996
BioChem Pharma Receives Patent For Lamivudine
15 July 1996
AIDS Meeting; Guarded Optimism Replaces Pessimism
15 July 1996
Glaxo Wellcome And Vertex Get HIV Patent License
8 July 1996
Can HIV be Eradicated From An Infected Person?
1 July 1996
Dutch Reimbursement Prices For Epivir And Norvir
10 June 1996
Lamivudine Counters HIV/HBV Co-Infection
20 May 1996
3TC Royalties Mean Profit For BioChem Pharma
13 May 1996
...And Backs Approval Of Glaxo Wellcome's Lamivudine
29 April 1996
-Epivir Approved In Australia
22 April 1996
Correction in GW share Price An Over-reaction?
22 April 1996
BioChem Posts Profits In 1995 4th Qtr
1 April 1996
Merck's Crixivan Is Third Protease Inhibitor Cleared
25 March 1996
Zantac Sales Slide 4% At Glaxo Wellcome
11 March 1996
Moves In HIV Therapy As FDA Panel Delivers Verdicts
4 March 1996
Triple Therapies For HIV Provide Encouraging Data
5 February 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
Oligonucleotides For Hep B From Innovir
22 January 1996
BioChem Pharma and GW get new Epivir approval
18 December 1995
First Launch Of Protease Inhibitor Raises Cost Concerns
18 December 1995
Treatment Of Chronic Hepatitis: New Options
4 December 1995
Glaxo Wellcome Set To Launch 3TC In Its First Market
27 November 1995
Glaxo Wellcome Unveils Revamped Pipeline
20 November 1995
3TC Gains FDA Panel Recommendation For Approval
13 November 1995
Glaxo Wellcome Revamps R&D To Treble Productivity
13 November 1995
EUROPEAN STOCK COMMENT
13 November 1995
GW's 3TC given tradename
16 October 1995
FDA Antiviral DAC review HIV treatments
9 October 1995
Two-Year Data For BioChem Pharma's 3TC
9 October 1995
Delta Trial Gives Boost To AIDS Community
2 October 1995
Increased Revenues For BioChem Pharma In 2nd Qtr
4 September 1995
Positive Study On BioChem Pharma's Lamivudine
4 September 1995
Glaxo Wellcome: Building For The Long Term
21 August 1995
BioPharma And XTL Biopharm Hepatitis Collaboration
14 August 1995
Glaxo Wellcome Files First Dossier For 3TC
10 July 1995
Lilly And US FTC Agree Over PCS Acquisition
5 June 1995
Glaxo limits supplies of 3TC to access program
29 May 1995
Biochem Pharma To File NDA For 3TC In June
15 May 1995
Roche's Saquinavir Safe In HIV-Infected Patients
24 April 1995
Expanded Access Urged For Protease Inhibitors
13 March 1995
Lamivudine/Zidovudine Combination Promising
13 February 1995
Glaxo, Wellcome Product Lines Are Complementary
6 February 1995
Lamivudine In AIDS: Ph II/III Results
6 February 1995
Uncertainty For Biochem Despite 3TC
12 December 1994
Biochem Execs Make Gains on 3TC Report
5 December 1994
European Stock Comment
28 November 1994
Lamivudine Enhances Zidovudine Efficacy
28 November 1994
Lamivudine: Positive Effects In Hepatitis B
21 November 1994
HIV Therapy Options Examined
31 October 1994
Wellcome Details HIV Research Plans
15 August 1994
BIOCHEM BUYS SERONO DIAGNOSTICS
11 July 1994
WELLCOME TO DEVELOP 3TC?
28 March 1994
GLAXO UPS BIOCHEM PHARMA INTEREST
28 February 1994
GLAXO REAFFIRMS COMMITMENT TO R&D
6 December 1993
3TC GAINS LIMITED CANADIAN APPROVAL
1 November 1993
FIALURIDINE TRIAL CASE HOTS UP
1 November 1993
LAMIVUDINE LAUNCH IN TWO YEARS?
26 July 1993
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
